Target Validation CROs

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Drug discovery and development company offering a range of discovery and preclinical services including target validation, hit identification, lead optimization, and ADME/PK.

Specialty CRO providing biochemical and cell-based assay services for drug discovery. Known for kinase profiling, epigenetic screening, and custom assay development.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

South Korean genomics and CRO company providing next-generation sequencing, genomic analysis, and precision medicine research services alongside clinical biomarker and pharmacogenomics programs.

Croatian integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, and preclinical development services, now part of Polish CRO Selvita Group.

Polish integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, computational chemistry, and preclinical services with 1,000+ scientists across Europe.

Hanover, Maryland-based drug screening CRO offering high-throughput receptor binding, enzyme inhibition, and functional cell-based assays for hit-to-lead optimisation programmes.

Global precision medicine CRO delivering biomarker and bioanalytical services including flow cytometry, histopathology, proteomics, and genomics for clinical trials.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

Preclinical neuroscience CRO spun out of GlaxoSmithKline in 2010, specializing in in vivo CNS pharmacology models for psychedelic compound and neurodegeneration research.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

Barcelona-based preclinical CRO pioneering zebrafish-based platforms for efficacy testing, safety pharmacology, and toxicity assessment of pharmaceutical and chemical compounds.

Boulder-based biologic discovery CRO integrating antibody discovery, protein engineering, function-first screening, and early developability assessment for complex biotherapeutics.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.